Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

54.98 +2.45 (+4.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 636,241
Open 52.60
Bid (Size) 54.00 (5)
Ask (Size) 57.50 (2)
Prev. Close 52.53
Today's Range 51.19 - 55.18
52wk Range 18.70 - 56.09
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily

Performance

YTD
+77.18%
+77.18%
1 Month
+34.85%
+34.85%
3 Month
+50.63%
+50.63%
6 Month
+34.10%
+34.10%
1 Year
+171.64%
+171.64%

More News

Read More
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
Via Benzinga
7 Biotech Stocks to Get In Now Before Investors Catch On
Via InvestorPlace
Analyst Ratings for Arcellx
Via Benzinga
Why Arcellx (ACLX) Stock Is Nosediving
Via Benzinga
The Latest Analyst Ratings for Arcellx
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
What 5 Analyst Ratings Have To Say About Arcellx
Via Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
Via InvestorPlace
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
Via Investor's Business Daily
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
Via Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.